The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Ropivacaine Mesylate Market Research Report 2024
Synopsis
Ropivacaine mesylate is a long-acting amide local anaesthetic agent for a spinal block and effectively blocks neuropathic pain. Ropivacaine blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibressup.
Global Ropivacaine Mesylate market is projected to reach US$ 1973.3 million in 2029, increasing from US$ 870 million in 2022, with the CAGR of 6.4% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Ropivacaine Mesylate market research.
Anesthetics are an indispensable class of important chemical substances in modern clinical surgery. The mechanism of action is to inhibit and block the conduction of nerve impulses. It plays an important role in alleviating the pain of patients and promoting the development of surgical medicine. With the development of medicine, more attention is paid to the patient's somatosensory, and the increase of painless surgery has promoted this market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Ropivacaine Mesylate market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer
Akorn
Anant Pharmaceuticals
SGPharma
Nephron Pharmaceuticals
Sintetica SA
AstraZeneca
Manus Aktteva Biopharma LLP
Zhejiang Xianju Pharmaceutical Co.,Ltd
Jiangsu Nhwa Pharmaceutical Co.,Ltd.
Yangzi River Pharmaceutical Group
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Jiangsu Nhwa Pharmaceutical Co.,Ltd
Segment by Type
2 mg/mL (0.2%)
5 mg/mL (0.5%)
7.5 mg/mL (0.75%)
10 mg/mL (1%)
Segment by Application
Surgical Anesthesia
Major Nerve Block
Acute Pain Management
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Ropivacaine Mesylate report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Ropivacaine mesylate is a long-acting amide local anaesthetic agent for a spinal block and effectively blocks neuropathic pain. Ropivacaine blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibressup.
Global Ropivacaine Mesylate market is projected to reach US$ 1973.3 million in 2029, increasing from US$ 870 million in 2022, with the CAGR of 6.4% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Ropivacaine Mesylate market research.
Anesthetics are an indispensable class of important chemical substances in modern clinical surgery. The mechanism of action is to inhibit and block the conduction of nerve impulses. It plays an important role in alleviating the pain of patients and promoting the development of surgical medicine. With the development of medicine, more attention is paid to the patient's somatosensory, and the increase of painless surgery has promoted this market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Ropivacaine Mesylate market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer
Akorn
Anant Pharmaceuticals
SGPharma
Nephron Pharmaceuticals
Sintetica SA
AstraZeneca
Manus Aktteva Biopharma LLP
Zhejiang Xianju Pharmaceutical Co.,Ltd
Jiangsu Nhwa Pharmaceutical Co.,Ltd.
Yangzi River Pharmaceutical Group
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Jiangsu Nhwa Pharmaceutical Co.,Ltd
Segment by Type
2 mg/mL (0.2%)
5 mg/mL (0.5%)
7.5 mg/mL (0.75%)
10 mg/mL (1%)
Segment by Application
Surgical Anesthesia
Major Nerve Block
Acute Pain Management
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Ropivacaine Mesylate report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Ropivacaine Mesylate Market Overview
1.1 Product Overview and Scope of Ropivacaine Mesylate
1.2 Ropivacaine Mesylate Segment by Type
1.2.1 Global Ropivacaine Mesylate Market Value Comparison by Type (2023-2029)
1.2.2 2 mg/mL (0.2%)
1.2.3 5 mg/mL (0.5%)
1.2.4 7.5 mg/mL (0.75%)
1.2.5 10 mg/mL (1%)
1.3 Ropivacaine Mesylate Segment by Application
1.3.1 Global Ropivacaine Mesylate Market Value by Application: (2023-2029)
1.3.2 Surgical Anesthesia
1.3.3 Major Nerve Block
1.3.4 Acute Pain Management
1.3.5 Other
1.4 Global Ropivacaine Mesylate Market Size Estimates and Forecasts
1.4.1 Global Ropivacaine Mesylate Revenue 2018-2029
1.4.2 Global Ropivacaine Mesylate Sales 2018-2029
1.4.3 Global Ropivacaine Mesylate Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Ropivacaine Mesylate Market Competition by Manufacturers
2.1 Global Ropivacaine Mesylate Sales Market Share by Manufacturers (2018-2023)
2.2 Global Ropivacaine Mesylate Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Ropivacaine Mesylate Average Price by Manufacturers (2018-2023)
2.4 Global Ropivacaine Mesylate Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Ropivacaine Mesylate, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Ropivacaine Mesylate, Product Type & Application
2.7 Ropivacaine Mesylate Market Competitive Situation and Trends
2.7.1 Ropivacaine Mesylate Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Ropivacaine Mesylate Players Market Share by Revenue
2.7.3 Global Ropivacaine Mesylate Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Ropivacaine Mesylate Retrospective Market Scenario by Region
3.1 Global Ropivacaine Mesylate Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Ropivacaine Mesylate Global Ropivacaine Mesylate Sales by Region: 2018-2029
3.2.1 Global Ropivacaine Mesylate Sales by Region: 2018-2023
3.2.2 Global Ropivacaine Mesylate Sales by Region: 2024-2029
3.3 Global Ropivacaine Mesylate Global Ropivacaine Mesylate Revenue by Region: 2018-2029
3.3.1 Global Ropivacaine Mesylate Revenue by Region: 2018-2023
3.3.2 Global Ropivacaine Mesylate Revenue by Region: 2024-2029
3.4 North America Ropivacaine Mesylate Market Facts & Figures by Country
3.4.1 North America Ropivacaine Mesylate Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Ropivacaine Mesylate Sales by Country (2018-2029)
3.4.3 North America Ropivacaine Mesylate Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Ropivacaine Mesylate Market Facts & Figures by Country
3.5.1 Europe Ropivacaine Mesylate Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Ropivacaine Mesylate Sales by Country (2018-2029)
3.5.3 Europe Ropivacaine Mesylate Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Ropivacaine Mesylate Market Facts & Figures by Country
3.6.1 Asia Pacific Ropivacaine Mesylate Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Ropivacaine Mesylate Sales by Country (2018-2029)
3.6.3 Asia Pacific Ropivacaine Mesylate Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Ropivacaine Mesylate Market Facts & Figures by Country
3.7.1 Latin America Ropivacaine Mesylate Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Ropivacaine Mesylate Sales by Country (2018-2029)
3.7.3 Latin America Ropivacaine Mesylate Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Ropivacaine Mesylate Market Facts & Figures by Country
3.8.1 Middle East and Africa Ropivacaine Mesylate Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Ropivacaine Mesylate Sales by Country (2018-2029)
3.8.3 Middle East and Africa Ropivacaine Mesylate Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Ropivacaine Mesylate Sales by Type (2018-2029)
4.1.1 Global Ropivacaine Mesylate Sales by Type (2018-2023)
4.1.2 Global Ropivacaine Mesylate Sales by Type (2024-2029)
4.1.3 Global Ropivacaine Mesylate Sales Market Share by Type (2018-2029)
4.2 Global Ropivacaine Mesylate Revenue by Type (2018-2029)
4.2.1 Global Ropivacaine Mesylate Revenue by Type (2018-2023)
4.2.2 Global Ropivacaine Mesylate Revenue by Type (2024-2029)
4.2.3 Global Ropivacaine Mesylate Revenue Market Share by Type (2018-2029)
4.3 Global Ropivacaine Mesylate Price by Type (2018-2029)
5 Segment by Application
5.1 Global Ropivacaine Mesylate Sales by Application (2018-2029)
5.1.1 Global Ropivacaine Mesylate Sales by Application (2018-2023)
5.1.2 Global Ropivacaine Mesylate Sales by Application (2024-2029)
5.1.3 Global Ropivacaine Mesylate Sales Market Share by Application (2018-2029)
5.2 Global Ropivacaine Mesylate Revenue by Application (2018-2029)
5.2.1 Global Ropivacaine Mesylate Revenue by Application (2018-2023)
5.2.2 Global Ropivacaine Mesylate Revenue by Application (2024-2029)
5.2.3 Global Ropivacaine Mesylate Revenue Market Share by Application (2018-2029)
5.3 Global Ropivacaine Mesylate Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Ropivacaine Mesylate Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Pfizer Ropivacaine Mesylate Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Akorn
6.2.1 Akorn Corporation Information
6.2.2 Akorn Description and Business Overview
6.2.3 Akorn Ropivacaine Mesylate Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Akorn Ropivacaine Mesylate Product Portfolio
6.2.5 Akorn Recent Developments/Updates
6.3 Anant Pharmaceuticals
6.3.1 Anant Pharmaceuticals Corporation Information
6.3.2 Anant Pharmaceuticals Description and Business Overview
6.3.3 Anant Pharmaceuticals Ropivacaine Mesylate Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Anant Pharmaceuticals Ropivacaine Mesylate Product Portfolio
6.3.5 Anant Pharmaceuticals Recent Developments/Updates
6.4 SGPharma
6.4.1 SGPharma Corporation Information
6.4.2 SGPharma Description and Business Overview
6.4.3 SGPharma Ropivacaine Mesylate Sales, Revenue and Gross Margin (2018-2023)
6.4.4 SGPharma Ropivacaine Mesylate Product Portfolio
6.4.5 SGPharma Recent Developments/Updates
6.5 Nephron Pharmaceuticals
6.5.1 Nephron Pharmaceuticals Corporation Information
6.5.2 Nephron Pharmaceuticals Description and Business Overview
6.5.3 Nephron Pharmaceuticals Ropivacaine Mesylate Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Nephron Pharmaceuticals Ropivacaine Mesylate Product Portfolio
6.5.5 Nephron Pharmaceuticals Recent Developments/Updates
6.6 Sintetica SA
6.6.1 Sintetica SA Corporation Information
6.6.2 Sintetica SA Description and Business Overview
6.6.3 Sintetica SA Ropivacaine Mesylate Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Sintetica SA Ropivacaine Mesylate Product Portfolio
6.6.5 Sintetica SA Recent Developments/Updates
6.7 AstraZeneca
6.6.1 AstraZeneca Corporation Information
6.6.2 AstraZeneca Description and Business Overview
6.6.3 AstraZeneca Ropivacaine Mesylate Sales, Revenue and Gross Margin (2018-2023)
6.4.4 AstraZeneca Ropivacaine Mesylate Product Portfolio
6.7.5 AstraZeneca Recent Developments/Updates
6.8 Manus Aktteva Biopharma LLP
6.8.1 Manus Aktteva Biopharma LLP Corporation Information
6.8.2 Manus Aktteva Biopharma LLP Description and Business Overview
6.8.3 Manus Aktteva Biopharma LLP Ropivacaine Mesylate Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Manus Aktteva Biopharma LLP Ropivacaine Mesylate Product Portfolio
6.8.5 Manus Aktteva Biopharma LLP Recent Developments/Updates
6.9 Zhejiang Xianju Pharmaceutical Co.,Ltd
6.9.1 Zhejiang Xianju Pharmaceutical Co.,Ltd Corporation Information
6.9.2 Zhejiang Xianju Pharmaceutical Co.,Ltd Description and Business Overview
6.9.3 Zhejiang Xianju Pharmaceutical Co.,Ltd Ropivacaine Mesylate Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Zhejiang Xianju Pharmaceutical Co.,Ltd Ropivacaine Mesylate Product Portfolio
6.9.5 Zhejiang Xianju Pharmaceutical Co.,Ltd Recent Developments/Updates
6.10 Jiangsu Nhwa Pharmaceutical Co.,Ltd.
6.10.1 Jiangsu Nhwa Pharmaceutical Co.,Ltd. Corporation Information
6.10.2 Jiangsu Nhwa Pharmaceutical Co.,Ltd. Description and Business Overview
6.10.3 Jiangsu Nhwa Pharmaceutical Co.,Ltd. Ropivacaine Mesylate Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Jiangsu Nhwa Pharmaceutical Co.,Ltd. Ropivacaine Mesylate Product Portfolio
6.10.5 Jiangsu Nhwa Pharmaceutical Co.,Ltd. Recent Developments/Updates
6.11 Yangzi River Pharmaceutical Group
6.11.1 Yangzi River Pharmaceutical Group Corporation Information
6.11.2 Yangzi River Pharmaceutical Group Ropivacaine Mesylate Description and Business Overview
6.11.3 Yangzi River Pharmaceutical Group Ropivacaine Mesylate Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Yangzi River Pharmaceutical Group Ropivacaine Mesylate Product Portfolio
6.11.5 Yangzi River Pharmaceutical Group Recent Developments/Updates
6.12 Jiangsu Hengrui Pharmaceuticals Co., Ltd.
6.12.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Corporation Information
6.12.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Ropivacaine Mesylate Description and Business Overview
6.12.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Ropivacaine Mesylate Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Ropivacaine Mesylate Product Portfolio
6.12.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Recent Developments/Updates
6.13 Jiangsu Nhwa Pharmaceutical Co.,Ltd
6.13.1 Jiangsu Nhwa Pharmaceutical Co.,Ltd Corporation Information
6.13.2 Jiangsu Nhwa Pharmaceutical Co.,Ltd Ropivacaine Mesylate Description and Business Overview
6.13.3 Jiangsu Nhwa Pharmaceutical Co.,Ltd Ropivacaine Mesylate Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Jiangsu Nhwa Pharmaceutical Co.,Ltd Ropivacaine Mesylate Product Portfolio
6.13.5 Jiangsu Nhwa Pharmaceutical Co.,Ltd Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Ropivacaine Mesylate Industry Chain Analysis
7.2 Ropivacaine Mesylate Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Ropivacaine Mesylate Production Mode & Process
7.4 Ropivacaine Mesylate Sales and Marketing
7.4.1 Ropivacaine Mesylate Sales Channels
7.4.2 Ropivacaine Mesylate Distributors
7.5 Ropivacaine Mesylate Customers
8 Ropivacaine Mesylate Market Dynamics
8.1 Ropivacaine Mesylate Industry Trends
8.2 Ropivacaine Mesylate Market Drivers
8.3 Ropivacaine Mesylate Market Challenges
8.4 Ropivacaine Mesylate Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
